Table 1.

Indication for Prosigna testing according to Swedish national guidelines from 2019 and adapted regionally. NHG; Nottingham Histologic Grade. * Pathology lab specific Ki67 limits; Karolinska, Södersjukhuset, St:Göran hospital low 0–14%, intermediate 15–22%, high 23–100%; Jönköping, low 0–11%, intermediate 12–21%, high 22–100%; Akademiska hospital, low 0–14%, intermediate 15–23%, high 24–100%.

2019 Stockholm Guidelines for Adjuvant Chemotherapy or Prosigna Test in ER-Positive (ER ≥ 10%), HER2-Negative, Node Negative, Postmenopausal Patients
Tumor Size	Low-Risk LumA-Like NHG-1, Low Ki67 * and PR ≥ 20%	Intermediate-Risk LumA/B-Like NHG-1/2 Intermediate Ki67 *	High-Risk LumB-Like NHG-3 or NHG-1/2 and High Ki67 *
<5 mm	No Chemo	No Chemo	No Chemo
6–10 mm	No Chemo	No Chemo	Prosigna
11–20 mm	No Chemo	Prosigna	Prosigna
>20 ≤ 50 mm	Prosigna	Prosigna	Prosigna or Chemo
>50 mm	Prosigna	Chemo	Chemo